PMC:7417114 / 49660-50076 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T254","span":{"begin":234,"end":238},"obj":"Body_part"},{"id":"T255","span":{"begin":312,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T73","span":{"begin":234,"end":238},"obj":"Body_part"},{"id":"T74","span":{"begin":312,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A73","pred":"uberon_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A74","pred":"uberon_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T480","span":{"begin":221,"end":246},"obj":"Disease"},{"id":"T481","span":{"begin":234,"end":246},"obj":"Disease"},{"id":"T482","span":{"begin":299,"end":324},"obj":"Disease"},{"id":"T483","span":{"begin":312,"end":324},"obj":"Disease"}],"attributes":[{"id":"A480","pred":"mondo_id","subj":"T480","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A481","pred":"mondo_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A482","pred":"mondo_id","subj":"T482","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A483","pred":"mondo_id","subj":"T483","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T572","span":{"begin":139,"end":145},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T573","span":{"begin":234,"end":238},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T574","span":{"begin":234,"end":238},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T575","span":{"begin":312,"end":316},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T576","span":{"begin":312,"end":316},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T428","span":{"begin":13,"end":21},"obj":"Chemical"},{"id":"T429","span":{"begin":146,"end":157},"obj":"Chemical"},{"id":"T430","span":{"begin":263,"end":274},"obj":"Chemical"},{"id":"T91806","span":{"begin":341,"end":352},"obj":"Chemical"}],"attributes":[{"id":"A428","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_90948"},{"id":"A429","pred":"chebi_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/CHEBI_25212"},{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_90943"},{"id":"A99113","pred":"chebi_id","subj":"T91806","obj":"http://purl.obolibrary.org/obo/CHEBI_90943"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1500","span":{"begin":92,"end":97},"obj":"Gene"}],"attributes":[{"id":"A1500","pred":"tao:has_database_id","subj":"1500","obj":"Gene:1576"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T136","span":{"begin":221,"end":246},"obj":"Phenotype"},{"id":"T137","span":{"begin":299,"end":324},"obj":"Phenotype"}],"attributes":[{"id":"A136","pred":"hp_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/HP_0006530"},{"id":"A137","pred":"hp_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/HP_0006530"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T401","span":{"begin":0,"end":22},"obj":"Sentence"},{"id":"T402","span":{"begin":23,"end":60},"obj":"Sentence"},{"id":"T403","span":{"begin":61,"end":101},"obj":"Sentence"},{"id":"T404","span":{"begin":102,"end":158},"obj":"Sentence"},{"id":"T405","span":{"begin":159,"end":208},"obj":"Sentence"},{"id":"T406","span":{"begin":209,"end":275},"obj":"Sentence"},{"id":"T407","span":{"begin":276,"end":281},"obj":"Sentence"},{"id":"T408","span":{"begin":282,"end":410},"obj":"Sentence"},{"id":"T409","span":{"begin":411,"end":416},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}

{"project":"2_test","denotations":[{"id":"32778962-29033419-84130733","span":{"begin":277,"end":280},"obj":"29033419"},{"id":"32778962-31241220-84130734","span":{"begin":412,"end":415},"obj":"31241220"}],"text":"Osimertinib (Tagrisso)\n(AstraZeneca) Cmax=6 h (median time);\nVd=986 L Metabolized mainly by CYP3A and\nmetabolized to two pharmacologically active metabolites,\nAZ7550 and AZ5105 80 mg tablet orally once daily;\n95% binding Interstitial lung disease associated with osimertinib;\n(221)\nthe incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports\n(222)"}